DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals. A key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability. The protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk. Longitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories. The DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Lesion at high risk for hepatocellular carcinoma (HCC) - (LI RADS 4-5)
Timeframe: Baseline visit
Lesion at high risk for hepatocellular carcinoma (HCC) - (LI RADS 4-5)
Timeframe: Visit 2 (6 months)
Lesion at high risk for hepatocellular carcinoma (HCC) - (LI RADS 4-5)
Timeframe: Visit 3 (12 months)
Lesion at high risk for hepatocellular carcinoma (HCC) - (LI RADS 4-5)
Timeframe: Visit 4 (18 months)
Lesion at high risk for hepatocellular carcinoma (HCC) - (US LI RADS 3)
Timeframe: Baseline visit
Lesion at high risk for hepatocellular carcinoma (HCC) - (US LI RADS 3)
Timeframe: Visit 2 (6 months)
Lesion at high risk for hepatocellular carcinoma (HCC) - (US LI RADS 3)
Timeframe: Visit 3 (12 months)
Lesion at high risk for hepatocellular carcinoma (HCC) - (US LI RADS 3)
Timeframe: Visit 4 (18 months)
The Muscle Assessment Score (MAsS)
Timeframe: Baseline visit
The Muscle Assessment Score (MAsS)
Timeframe: Visit 2 (12 months)
The Muscle Assessment Score (MAsS)
Timeframe: Visit 3 (12 months)
The Muscle Assessment Score (MAsS)
Timeframe: Visit 4 (18 months)
Liver associated clinical events (LACE)
Timeframe: From enrollment and six months after the last study visit (after a total of 24 months).